Moy Beverly, Jagsi Reshma, Gaynor Richard B, Ratain Mark J
From the Massachusetts General Hospital Cancer Center, Boston, MA; University of Michigan, Ann Arbor, MI; Eli Lilly and Company, Indianapolis, IN; The University of Chicago, Chicago, IL.
Am Soc Clin Oncol Educ Book. 2015:130-7. doi: 10.14694/EdBook_AM.2015.35.130.
Public scrutiny has increased over potential conflicts of interest among oncology researchers and providers. Given the increased prevalence and complexity of industry relationships, oncologists are increasingly faced with ethical challenges when navigating their financial relationships with industry. Oncologists are continually dealing with changing conflict of interest policies within academic centers and professional societies. With the recent passage of The Sunshine Act, oncologists are beginning to understand the repercussions of this new law. The consequences of the increasing use of direct-to-consumer advertising on patients with cancer are also unclear. Finally, industry's perspective on the evolution of these relationships is not clearly understood. This manuscript discusses issues related to industry's influence on oncology practice and research.
公众对肿瘤学研究人员和医疗服务提供者之间潜在的利益冲突的审查日益增加。鉴于行业关系的日益普遍和复杂，肿瘤学家在处理与行业的财务关系时，面临着越来越多的伦理挑战。肿瘤学家不断应对学术中心和专业协会内不断变化的利益冲突政策。随着《阳光法案》的最近通过，肿瘤学家开始理解这项新法律的影响。直接面向消费者的广告在癌症患者中日益增加的使用所产生的后果也尚不清楚。最后，行业对这些关系演变的看法也未得到明确理解。本手稿讨论了与行业对肿瘤学实践和研究的影响相关的问题。
